About Us
Conditions & Procedures
Conditions
Procedures
Faculty
Patient Center
Education & Training
Research
News & Events
Make a Gift
A gift to the Department of Surgery helps our physicians and scientists find new treatments and cures for serious diseases.
Legendary Surgeon Maurice Galante Dies
Maurice Galante, M.D., a legendary master surgeon at UCSF and renaissance man, died on February 5, 2013. His career is memorialized by the Maurice Galante Lecture Program and Maurice Galante Distinguished Professorship.
Daniel J. Cook, Ph.D.
Adjunct Instructor
Interim Director,
Immunogenetics and Transplantation Lab
Contact Information
University of California, San Francisco
San Francisco, CA. 94143 - 0104
(415) 476-3883
Daniel.Cook@ucsfmedctr.org
BiographyEducation
- B.S., University of Massachusetts1979 Amherst, Massachusetts
- Ph.D., University of Florida1985 Gainesville, Florida
Postdoctoral Training
- Postdoctoral Fellow, 1985 Bowman Gray School of Medicine Winston-Salem, North Carolina
- Postdoctoral Fellow,1985-87 UCLA Tissue Typing Laboratory Los Angeles, California
Board Certification
- Certified Clinical Histocompatibility Laboratory Director, American Board of Histocompatibility and Immunogenetics, October.
- Certification as High-Complexity Clinical Laboratory Director by the American Board of Bioanalysis
- Laboratory Director for Histocompatibility and Engraftment Monitoring, New York
- Histocompatibility Laboratory Director, California
Research Interests
- "Desensitization" of patients with anti-HLA antibodiesn.
- Flow cytometric evaluation of MHC expression in solid organ transplants.
- Issues affecting equity in organ allocation.
- Molecular approaches for histocompatibility testing.
- Significance of pre- and posttransplant anti-donor antibodies in clinical allotransplantation.
- The relationship between anti-HLA antibodies and vascular rejection of solid organ transplants.
Biography
Daniel J. Cook, Ph.D. is an Adjunct Instructor in the Department of Surgery and Interim Director of the Immunogenetics and Transplantation Lab. Dr. Cook received a B.S.from the University of Massachusetts in 1979 and a Ph.D. from the University of Florida in 1985.
He is a certified as a Clinical Histocompatibility Laboratory Director and as a High-Complexity Clinical Laboratory Director.He is the author of over one-hundred forty (140) publications and a frequent speaker at symposiums on this area of expertise. He was formerly the Co-Director of the Transplant Laboratory at the Baylor College of Medicine in Houston,Texas.
He is a member of numerous professional societies including The Transplantation Society, American Society for Histocompatibility and Immunogenetics, American Society of Transplant Physicians, and International Society for Heart and Lung Transplantation and has held numerous leadership roles on committees within these and other organizations.
Research Summary
During his career, Dr. Cook's research has spanned numerous fields including Human transplantation immunology including alloantibody charac-terization, tissue typing, immune function assays (MLC, CML, mi-togens), flow cytometric crossmatching and transplant monitoring; flow cytometry; sero¬logical and biochemical characterization of histocompatibility anti¬gens; hybridoma technology; ELISA; T cell culture; lymphokinesion; anti-thymocyte globulin production; HLA-class II typing by molecular techniques (by SSOP, PCR-RFLP, sequencing), cyclosporine A monitoring by HPLC, RIA and TDx.
Selected Publications
-
Gonzalez-Stawinski GV, Cook DJ, Smedira NG, Navia JL, Taylor DO, Yamani MH,Hoercher K, Starling RC, Banbury MK. Attrition from heart transplant waiting list for patients on ventricular assistdevices is not affected by desensitization strategies.Transplant Proc. 2007 Jun;39(5):1571-2.
-
Flechner SM, Goldfarb D, Solez K, Modlin CS, Mastroianni B, Savas K, BabineauD, Kurian S, Salomon D, Novick AC, Cook DJ. Kidney transplantation with sirolimus and mycophenolate mofetil-basedimmunosuppression: 5-year results of a randomized prospective trial compared tocalcineurin inhibitor drugs.Transplantation. 2007 Apr 15;83(7):883-92.
-
Yamani MH, Taylor DO, Rodriguez ER, Cook DJ, Zhou L, Smedira N, Starling RC. Transplant vasculopathy is associated with increased AlloMap gene expressionscore.J Heart Lung Transplant. 2007 Apr;26(4):403-6.
-
Detection of HLA-Specific Alloantibody by Flow Cytometry and Solid Phase Assays; Approved Guideline. Cook DJ, Balzas, I, Baxter-Lowe LA, Crose DO, Marti GE, Murphey C, Nelson K, Vogt RF, Ward WW. Clinical and Laboratory Standards Institute, 2009, In Press. 2012 Apr;12(4):1004-16.
-
144) Graft vasculopathy in clinical hand transplantation. Kaufman CL, Ouseph R, Blair B, Kutz JE, Tsai TM, Scheker LR, Tien HY, Moreno R, Ozyurekoglu T, Banegas R, Murphy E, Burns CB, Zaring R, Cook DF, Marvin MR. Am J Transplant. 2012 Apr;12(4):1004-16.
